NOVATO, Calif., May 26 /PRNewswire/ -- Raptor Pharmaceutical Inc. ("Raptor") announced today the completion of a reverse merger of Highland Clan Creations Corp. (OTC:HCLN) (BULLETIN BOARD: HCLN) in a stock-for-stock exchange. Highland sold all of its prior operations as a nutritional drink distributor in April 2006. Effective June 9, 2006, Highland will reincorporate in Delaware from Nevada and will change its name to Raptor Pharmaceuticals Corp. Highland, which now owns 100% of the operating company, Raptor Pharmaceutical Inc., will be assigned a new ticker symbol on the OTCBB once the reincorporation and name change to Raptor Pharmaceuticals Corp. are concluded. Concurrent with the purchase of Raptor, Highland completed a $5 million financing today. The financing consisted of 8,333,333 units at $.60 per unit. Each unit consists of one share of common stock of Highland and one warrant to purchase one share of common stock of Highland. The warrants are exercisable at an exercise price of $0.60 per share and terminate after 18 months. Net proceeds, after expenses and the repayment of a third-party bridge loan, were approximately $4.5 million. Raptor intends to use the net proceeds for the continued research and development of drug product candidates for the potential treatment of neurodegenerative diseases, metabolic diseases and cancer. About Raptor Raptor Pharmaceutical Inc., an early stage biotechnology research and development company, bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. On January 27, 2006, Raptor purchased from BioMarin Pharmaceutical Inc. the intellectual property for the RAP technology and related programs. "We believe that our RAP technology will allow for selective therapeutic targeting of organs, tissues and cell types through the use of specific receptor systems," said Christopher Starr, Ph.D., co-founder and Chief Executive Officer. "The neurological application of our RAP technology, named NeuroTrans(TM), has already demonstrated the potential to deliver therapeutic proteins across the blood-brain barrier to the brain in early non-clinical studies." Todd Zankel, Ph.D., co-founder and Chief Scientific Officer stated, "We are excited to have the opportunity to further develop Raptor's approaches to treating a variety of diseases. We look forward to the work ahead, both on-site in Novato and in the labs of our academic collaborators." "We've assembled a dedicated, experienced team that is passionate about the RAP technology and its potential broad clinical applications. We are appreciative of the support of our early investors which allows the Raptor team to continue this vital research," said Kim Tsuchimoto, Chief Financial Officer. Details about the reincorporation, name change, reverse merger and financing can be found in Highland's Form 14C filed on May 17, 2006 and Current Report on Form 8-K filed today on the SEC's website (http://www.sec.gov/). Additional information about Raptor can be found at http://www.raptorpharma.com/. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. FORWARD LOOKING STATEMENTS This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to, the following statements: that Highland will reincorporate in Delaware from Nevada and change its name to Raptor Pharmaceuticals Corp.; that we intend to use the net proceeds from the financing for the continued research and development of drug product candidates for the potential treatment of neurodegenerative diseases, metabolic diseases and cancer; that our RAP technology will allow the selective and therapeutic targeting of organs, tissues and cell types through the use of specific receptor systems; that NeuroTrans(TM), has the potential to deliver therapeutic proteins across the blood-brain barrier to the brain; statements relating to our ability to raise sufficient capital to finance our planned operations, our ability to develop viable drug product candidates; that we have the opportunity to fully develop Raptor's approaches to a variety of diseases; that we will be able to continue our research; and that our research and products have the potential for treatment of serious, life- threatening diseases and conditions. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward- looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that regulatory requirements may prevent Highland from taking corporate reorganization steps it intends; we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's Current Report on Form 8-K filed with the SEC on May 26, 2006. DATASOURCE: Raptor Pharmaceutical Inc. CONTACT: Kim Tsuchimoto, CFO, Treasurer and Secretary of Raptor Pharmaceutical Inc., +1-415-382-1390, or Web site: http://www.raptorpharma.com/

Copyright